Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 219Rectal Neoplasms 137Stomach Neoplasms 95Colonic Neoplasms 87Pancreatic Neoplasms 82Esophageal Neoplasms 71Neoplasm Metastasis 58Squamous Cell Carcinoma of Head and Neck 43Head and Neck Neoplasms 42Adenocarcinoma Of Esophagus 37Neoplasms 36Breast Neoplasms 35Esophageal Squamous Cell Carcinoma 27Carcinoma, Hepatocellular 22Cholangiocarcinoma 21Adenocarcinoma 17Nasopharyngeal Carcinoma 16Bile Duct Neoplasms 14Gallbladder Neoplasms 13Carcinoma, Squamous Cell 13Biliary Tract Neoplasms 13Anus Neoplasms 13Urinary Bladder Neoplasms 11Liver Neoplasms 10Carcinoma 9Nasopharyngeal Neoplasms 8Colorectal Cancer Metastatic 8Peritoneal Neoplasms 7Recurrence 6Ovarian Neoplasms 6

Interventions

Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × mCRC × Fluorouracil × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡